- Ocumetics Technology (TSXV:OTC) has completed the biocompatibility study of its accommodating intraocular lens in the eyes of rabbits
- The Ocumetics Accommodating Lens was compared to a commercially available monofocal intraocular lens
- Results from the animal study indicated there were no biocompatibility or safety issues
- Shares of Ocumetics Technology are unchanged at C$0.33
Ocumetics Technology (TSXV:OTC) has completed the biocompatibility study of its accommodating intraocular lens in the eyes of rabbits.
The company stated in a news release that its Occumetics Accommodating Lens was compared to a commercially available monofocal intraocular lens as a control.
The three-month animal study showed there were no biocompatibility or safety issues of the Ocumetics Accommodating Lens when compared to the standard monofocal intraocular lens.
The Occumetics Accommodating Lens aims to mimic the natural lens of the eye and provide clear distance and near vision without glasses or contact lenses.
“Our primary focus in this study was to assess the surgical implantation performance of our revolutionary accommodating intraocular lens design,” Dr. Garth Webb, founder and chief scientific officer of Ocumetics Technology, said in a statement. “This marks the realization of years of dedicated technological advancement.”
Thanks to the successful animal trial, Ocumetics CEO Dean Burns said this is crucial for the company as it marches towards U.S. Food and Drug Administration approval. The company anticipates beginning its first-in-human proof of concept study in the first quarter of 2024.
Ocumetics Technology is focused on developing and commercializing advanced vision correction solutions.
Shares of Ocumetics Technology are unchanged at C$0.33.
Join the discussion: Find out what everybody’s saying about this stock on the Ocumetics Technology Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
